Medtronic plc (MDT) has released the results of a clinical study showcasing the efficacy of the PulseSelect Pulsed Field Ablation (PFA) System in treating atrial fibrillation (Afib). The study revealed a 98% rate of durable lesion formation in pulmonary veins (PV) approximately two months after ablation, with 96% of patients achieving full isolation of all veins.
Atrial fibrillation (Afib), a prevalent yet often inadequately treated heart rhythm disorder, affects over 60 million individuals globally.